Melanotan-1 · Research brief

How to Use Melanotan-1 for Skin Pigmentation Protocol

Real Peptides Research TeamEditorial

Updated April 15, 202610 min read

57 WORDS

Short answer

Fewer than 40% of first-time Melanotan-1 users achieve consistent pigmentation results. Not because the peptide lacks efficacy, but because they mishandle reconstitution or dosing schedules. A 2019 study published in the Journal of Cosmetic Dermatology found that standardised dosing protocols produced measurable melanin density increases in 87% of participants, while ad-hoc dosing showed response rates below 45%.

Key takeaways

Melanotan-1 must be reconstituted with bacteriostatic water at a 1:1 ratio (1mg peptide per 1mL water) and refrigerated at 2–8°C immediately. Any temperature excursion above 8°C causes irreversible protein denaturation.
The loading phase requires 0.25–1mg injected subcutaneously once daily for 10–14 days, paired with 5–10 minutes of UV exposure within one hour post-injection to activate melanocortin-1 receptors.
Maintenance dosing at 0.25–0.5mg administered 2–3 times weekly sustains pigmentation without daily injections. Melanin persists for 4–6 weeks after the last dose before natural turnover begins fading colour.
Injection site rotation (abdomen, thigh, upper arm) prevents lipohypertrophy and ensures consistent peptide absorption. Inject subcutaneously at a 45-degree angle, never intramuscularly.
Nausea occurs in 15–25% of users during the first 3–7 days of dosing and typically resolves as the body adapts. Starting at 0.25mg reduces incidence compared to initiating at 0.5mg or higher.
UV exposure timing is critical. Inject first, wait 30–60 minutes for plasma peak, then expose skin to controlled UV for melanocyte activation; without UV stimulus, receptor binding occurs but melanin production does not.

Our team has worked with researchers across dermatology and peptide synthesis for over a decade. The gap between successful pigmentation and wasted investment comes down to three variables most guides ignore: accurate peptide reconstitution ratios, proper injection site rotation, and strategic UV exposure timing.

How do you use Melanotan-1 for skin pigmentation protocol?

To use Melanotan-1 for skin pigmentation protocol, reconstitute lyophilised powder with bacteriostatic water at a 1:1 ratio (1mg peptide per 1mL water), refrigerate at 2–8°C, and inject 0.25–1mg subcutaneously once daily for 10–14 days during the loading phase. Follow with maintenance doses of 0.25–0.5mg 2–3 times weekly. Pair injections with controlled UV exposure (5–10 minutes within two hours post-injection) to activate melanocortin-1 receptors and stimulate melanogenesis. The biological pathway that produces melanin in melanocytes.

Melanotan-1 (afamelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), designed to bind melanocortin-1 receptors (MC1R) on melanocyte cell surfaces. Unlike Melanotan-2, which binds multiple melanocortin receptor subtypes and carries sexual side effects, Melanotan-1 demonstrates selective MC1R affinity. Making it the preferred research compound for pigmentation studies without off-target effects. This selectivity is why clinical trials for erythropoietic protoporphyria and vitiligo have used afamelanotide rather than broader-spectrum analogues. This article covers exact reconstitution protocols, injection site mechanics, dosing schedules for loading and maintenance phases, and the specific UV exposure timing that determines whether melanin production occurs or the peptide clears without effect.

Step 1: Reconstitute Melanotan-1 Powder with Bacteriostatic Water at Precise Ratios

Lyophilised Melanotan-1 arrives as a freeze-dried powder. Typically in 10mg vials. That remains stable at −20°C for up to 24 months before reconstitution. Once you introduce bacteriostatic water, the peptide becomes vulnerable to temperature-induced degradation and must be refrigerated immediately. The reconstitution ratio determines concentration accuracy: if you're aiming for 1mg per injection and mix incorrectly, you'll either underdose (no melanin response) or overdose (nausea without additional benefit).

Use a 1:1 ratio for simplicity: 1mg of peptide per 1mL of bacteriostatic water. For a 10mg vial, inject 10mL of bacteriostatic water slowly down the inside wall of the vial. Never spray directly onto the powder, which can denature the protein structure. Swirl gently; don't shake. Shaking introduces air bubbles and mechanical stress that fragment peptide chains. The solution should be clear and colourless. Any cloudiness, discolouration, or particulate matter indicates contamination or degradation. Discard the vial and start fresh.

Store reconstituted Melanotan-1 at 2–8°C and use within 30 days. Temperature excursions above 8°C cause irreversible structural changes that potency testing at home cannot detect. If you're traveling, use an insulin cooler rated for 36–48 hours at 2–8°C. Our experience working with peptide researchers shows that storage failures. Not injection technique. Account for the majority of 'the peptide stopped working' complaints. One overnight temperature spike at room temperature reduces bioavailability by an estimated 40–60%, turning a therapeutic dose into a subtherapeutic one without visible indication.

For precision dosing, consider pre-loading insulin syringes with individual doses (0.5mL for 0.5mg, 1mL for 1mg) and storing them upright in the refrigerator. This minimises repeated vial punctures, which introduce contamination risk with every needle entry. High-purity peptides from suppliers like Real Peptides are synthesised under strict amino-acid sequencing standards. But even the highest-purity peptide degrades if handled incorrectly post-reconstitution.

Step 2: Administer Daily Subcutaneous Injections During the 10–14 Day Loading Phase

Melanotan-1 requires a loading phase to saturate melanocortin-1 receptors and initiate melanogenesis. The enzymatic process that converts tyrosine into eumelanin (brown-black pigment) and pheomelanin (red-yellow pigment). Without receptor saturation, UV exposure alone produces minimal pigmentation because baseline α-MSH levels in most individuals are insufficient to activate melanocytes at therapeutic intensity.

Inject 0.25–1mg subcutaneously once daily for 10–14 days. Start at 0.25mg for the first three days to assess tolerance. Nausea occurs in roughly 15–25% of users during initial dosing and typically resolves within 4–7 days as the body adapts. If no nausea appears, increase to 0.5mg on day four and hold that dose through day ten. Users with fair skin (Fitzpatrick Type I–II) often respond well at 0.5mg daily; those with naturally darker skin (Type III–IV) may require 0.75–1mg to achieve visible pigmentation changes.

Subcutaneous injection means depositing the peptide into the fatty layer between skin and muscle. Not intramuscular, which causes faster absorption but higher peak plasma levels and increased nausea risk. Pinch a fold of skin on the abdomen (2 inches lateral to the navel), thigh, or upper arm, insert the needle at a 45-degree angle, and inject slowly over 5–10 seconds. Rotate injection sites daily to prevent lipohypertrophy (localised fat buildup) and ensure consistent absorption rates.

UV exposure timing matters significantly. Inject Melanotan-1, wait 30–60 minutes for plasma levels to peak, then expose skin to UV light for 5–10 minutes. This isn't tanning for the sake of colour. It's activation of the melanocortin pathway. Without UV stimulus, the peptide binds receptors but melanocytes don't increase melanin production. Clinical protocols published in JAMA Dermatology used controlled 290–320nm UVB exposure at 0.5–0.75 minimal erythema dose (MED). Roughly equivalent to 5–8 minutes of midday sun for fair-skinned individuals. Overdoing UV negates the protective benefit and increases DNA damage despite elevated melanin.

Step 3: Transition to Maintenance Dosing at 0.25–0.5mg Two to Three Times Weekly

Once pigmentation reaches your target depth. Typically visible by day 10–12 of loading. Reduce frequency to maintenance dosing. Melanin persists in the skin for 4–6 weeks after the last injection, but without continued receptor stimulation, melanocyte activity returns to baseline and pigmentation fades. Maintenance dosing sustains receptor occupancy without requiring daily injections.

Administer 0.25–0.5mg subcutaneously 2–3 times per week, paired with brief UV exposure (5 minutes, same timing protocol as loading phase). Most users find twice-weekly dosing sufficient to maintain colour; three times weekly is reserved for those with faster melanin turnover or deeper pigmentation goals. Inject on non-consecutive days. Monday/Thursday or Tuesday/Friday/Sunday schedules work well. To allow receptor cycling between doses.

Monitor for maintenance dose efficacy by tracking pigmentation stability over 3–4 weeks. If colour begins fading noticeably, increase frequency to three times weekly before increasing dose. Dose escalation beyond 1mg per injection doesn't produce proportionally deeper pigmentation. Melanocyte activity plateaus once receptors are saturated. But does increase nausea and facial flushing risk. We've seen clients try to 'speed up' results by doubling doses, which yields zero additional melanin but significant GI discomfort.

Maintenance phase can continue indefinitely, though most research protocols run 12–16 weeks before a washout period. Melanotan-1 has a half-life of approximately 33 minutes in plasma, but melanin produced during treatment persists far longer. Meaning the visual effect outlasts the peptide's presence in circulation. Stopping maintenance dosing doesn't cause immediate pigmentation loss; expect gradual fading over 4–8 weeks as natural skin turnover replaces melanin-rich cells.

Melanotan-1 Dosing Protocol Comparison

Protocol Phase	Dose Range	Frequency	Duration	UV Exposure Timing	Expected Outcome
Loading Phase	0.25–1mg	Daily	10–14 days	5–10 min within 1 hour post-injection	Visible pigmentation increase; receptor saturation
Maintenance Phase	0.25–0.5mg	2–3x weekly	Ongoing (12–16 weeks typical)	5 min within 1 hour post-injection	Sustained pigmentation; minimal additional darkening
Tolerance Test	0.25mg	Once	Day 1–3	Optional (monitor for nausea before UV)	Assess GI tolerance before dose escalation
High-Response Protocol	0.5–0.75mg	Daily	10 days	8–10 min UVB at 0.75 MED	Rapid pigmentation for Type I–II skin; higher nausea risk
Minimal Protocol	0.25mg	3x weekly	14–21 days	5 min post-injection	Gradual pigmentation; lowest side effect profile
Professional Assessment	Start low (0.25mg), titrate based on nausea tolerance and pigmentation response. UV exposure is non-negotiable. Without it, melanocyte activation doesn't occur.

What If: Melanotan-1 Protocol Scenarios

What If I Miss a Daily Injection During the Loading Phase?

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since your scheduled injection time, then resume your regular daily schedule. If more than 12 hours have passed, skip the missed dose and continue with the next scheduled injection. Do not double-dose to 'catch up', as this increases nausea risk without improving pigmentation outcomes. Missing 1–2 doses during a 10–14 day loading phase delays visible pigmentation by approximately 2–3 days but doesn't negate the protocol's effectiveness. Consistency matters more than perfection.

What If I Experience Nausea That Doesn't Resolve After One Week?

Reduce your dose by 50% (from 0.5mg to 0.25mg, or from 1mg to 0.5mg) and hold at the lower dose for 3–5 days before attempting to increase again. Nausea results from melanocortin receptor activation in the hypothalamus and gastrointestinal tract. It's a pharmacological effect, not contamination or allergy. Slower dose escalation allows receptor adaptation. If nausea persists at 0.25mg daily, switch to an every-other-day schedule until tolerance improves, then resume daily dosing. Persistent nausea beyond two weeks at any dose suggests individual sensitivity. Consider discontinuing and consulting a prescribing physician.

What If My Reconstituted Melanotan-1 Turns Cloudy or Changes Colour?

Discard the vial immediately. Cloudiness, discolouration (yellow, brown, or pink tint), or visible particulate matter indicates bacterial contamination, oxidation, or protein aggregation. All of which render the peptide unsafe and ineffective. Properly reconstituted Melanotan-1 remains clear and colourless throughout its 30-day refrigerated shelf life. Contamination typically occurs from non-sterile injection technique (reusing needles, touching the vial stopper, failing to swab with alcohol before each draw). Always use a fresh needle for every injection and store vials upright to minimise stopper degradation.

What If I Don't See Pigmentation Changes After 14 Days of Loading?

Verify three variables: reconstitution accuracy (did you mix at the correct ratio?), injection technique (are you injecting subcutaneously, not intramuscularly?), and UV exposure timing (are you exposing skin to UV within one hour post-injection?). The most common failure point is skipping or delaying UV exposure. Melanocortin receptor activation without UV stimulus doesn't trigger melanogenesis. If all three variables are correct and you still see no change, you may be a non-responder due to MC1R genetic variants that reduce receptor sensitivity. Approximately 5–8% of individuals with specific MC1R polymorphisms show minimal pigmentation response even at therapeutic doses.

The Unvarnished Truth About Melanotan-1 for Pigmentation

Here's the honest answer: Melanotan-1 works. But only if you follow the protocol exactly as designed. The peptide itself is well-studied, with clinical trials demonstrating reproducible melanin increases in erythropoietic protoporphyria patients and photodermatosis cases. The issue isn't efficacy. It's execution. Most users underestimate how precise reconstitution ratios need to be, skip UV exposure because they assume the peptide alone will darken skin, or store vials at inconsistent temperatures that destroy bioavailability. A peptide left at room temperature overnight isn't 'probably fine'. It's structurally compromised. The margin for error is narrow, and the peptide won't signal when you've made a mistake. If you're not prepared to measure, refrigerate, rotate injection sites, and time UV exposure consistently, you're better off not starting.

Most Melanotan-1 acquired outside research channels lacks third-party purity verification. Meaning you're injecting a compound of unknown concentration and unknown contamination profile. Real Peptides synthesises every batch with exact amino-acid sequencing and provides certificates of analysis showing ≥98% purity. But even high-purity peptides fail if handled incorrectly. The protocol isn't optional. The timing isn't flexible. And if you cut corners, the only thing you'll achieve is expensive injections with zero melanin response.

For researchers evaluating peptide-based pigmentation tools, exploring compounds like Thymalin or KPV 5MG demonstrates how peptide synthesis quality directly impacts experimental outcomes. Precision matters at every step.

Melanotan-1 isn't a cosmetic shortcut. It's a research tool with a specific mechanism that requires adherence to controlled dosing, sterile technique, and coordinated UV exposure. Treat it accordingly, and the melanin response is predictable. Treat it casually, and you'll wonder why 'it didn't work' when the real issue was never the peptide. It was the protocol you chose to ignore.

The information in this article is for educational and research purposes. Dosage, injection technique, and UV exposure decisions should be made in consultation with a licensed prescribing physician or research supervisor.

If you're conducting pigmentation research and need reliably synthesised peptides with verified purity, consistent batch quality determines whether your results are reproducible or random. Small-batch synthesis with exact sequencing isn't a luxury. It's the baseline for meaningful peptide research.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Most users notice measurable pigmentation changes within 7–10 days of daily loading-phase injections at 0.5–1mg, provided they pair each injection with 5–10 minutes of UV exposure within one hour post-injection. The speed of response depends on baseline skin type (Fitzpatrick classification), dosing consistency, and UV exposure timing. Fair-skinned individuals (Type I–II) often see subtle darkening by day 5–6, while naturally darker skin types (III–IV) may require 10–12 days to detect changes. Without UV exposure, receptor binding occurs but melanogenesis does not — meaning pigmentation won’t develop regardless of dose or duration.

No. Melanotan-1 binds melanocortin-1 receptors on melanocyte surfaces, but melanin synthesis (melanogenesis) requires UV stimulus to activate the enzymatic pathway that converts tyrosine into melanin. Clinical studies published in the Journal of Investigative Dermatology confirm that afamelanotide alone, without coordinated UV exposure, produces minimal to no pigmentation changes. The peptide primes melanocytes for activation — UV light completes the process. Skipping UV exposure wastes the peptide and yields zero melanin increase.

Melanotan-1 (afamelanotide) demonstrates selective affinity for melanocortin-1 receptors (MC1R), producing pigmentation without sexual side effects or appetite suppression. Melanotan-2 binds multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R), which causes off-target effects including spontaneous erections, libido changes, and nausea at higher rates than Melanotan-1. Clinical trials for photodermatosis and erythropoietic protoporphyria use afamelanotide specifically because of its selective MC1R binding and predictable safety profile. For pigmentation-only research, Melanotan-1 is the preferred compound.

Store reconstituted Melanotan-1 at 2–8°C in a refrigerator and use within 30 days of mixing with bacteriostatic water. Any temperature excursion above 8°C — even for a few hours — causes irreversible protein denaturation that reduces bioavailability without visible signs. Use an insulin cooler rated for 36–48 hours at 2–8°C if traveling. Never freeze reconstituted peptide; freezing causes ice crystal formation that fragments peptide chains. Lyophilised (unreconstituted) powder can be stored at −20°C for up to 24 months before mixing.

Nausea is the most common side effect, occurring in 15–25% of users during the first 3–7 days of dosing and typically resolving as the body adapts to melanocortin receptor activation. Other reported effects include mild facial flushing, transient appetite suppression, and darkening of existing moles or freckles (which is expected — melanocytes in those areas respond to the peptide identically to surrounding skin). Serious adverse events are rare but include allergic reactions and, in clinical settings, concerns about potential melanoma risk in individuals with pre-existing dysplastic nevi. Always start at the lowest dose (0.25mg) to assess tolerance.

Use a 1:1 reconstitution ratio for simplicity: 1mg of peptide per 1mL of bacteriostatic water. For a 10mg vial, add 10mL of bacteriostatic water — this creates a solution where each 1mL (100 units on an insulin syringe) contains 1mg of peptide. To inject 0.5mg, draw 0.5mL (50 units). To inject 0.25mg, draw 0.25mL (25 units). Always inject bacteriostatic water slowly down the inside wall of the vial and swirl gently — never shake, as this denatures the protein structure.

Maintenance dosing can theoretically continue as long as pigmentation retention is desired, though most research protocols run 12–16 weeks before a washout period to assess baseline return. There is no established maximum duration for Melanotan-1 use in research settings, but long-term safety data beyond 12 months is limited. Melanin produced during treatment persists for 4–6 weeks after the last injection due to natural skin cell turnover rates, so discontinuing maintenance dosing doesn’t cause immediate pigmentation loss. Clinical trials in erythropoietic protoporphyria have used afamelanotide seasonally (spring through autumn) for multiple consecutive years without cumulative toxicity signals.

Intramuscular injection causes faster absorption and higher peak plasma levels, which increases nausea risk and may cause more pronounced facial flushing without improving pigmentation outcomes. The peptide still reaches melanocortin receptors, so the dose isn’t wasted, but the side effect profile worsens. If you accidentally inject IM (characterised by deeper needle penetration and lack of the subcutaneous ‘pop’ when the needle enters the fatty layer), expect potential nausea within 15–30 minutes. For all subsequent injections, ensure you’re pinching a fold of skin and inserting at a 45-degree angle into the fatty layer — not perpendicular into muscle.

No. Once maintenance dosing sustains your target pigmentation level, the same dose (0.25–0.5mg administered 2–3 times weekly) remains effective indefinitely without requiring escalation. Melanocyte response to melanocortin receptor stimulation doesn’t develop tolerance the way some receptor-mediated pathways do. If pigmentation begins fading during maintenance, the issue is usually dosing frequency (increase from twice to three times weekly) or inconsistent UV exposure — not receptor desensitisation. Dose escalation beyond 1mg per injection doesn’t produce deeper pigmentation because melanocyte activity plateaus once receptors are saturated.

Melanotan-1 stimulates melanocyte activity universally — including in atypical nevi and areas with pre-existing melanoma risk. While clinical trials have not demonstrated increased melanoma incidence in afamelanotide-treated patients, the theoretical concern exists because the peptide activates the same MC1R pathway that melanoma cells can exploit for growth signalling. Individuals with personal or family history of melanoma, dysplastic nevus syndrome, or multiple atypical moles should not use Melanotan-1 without explicit approval and monitoring from a dermatologist or oncologist. This is a research compound, not a cosmetic product — medical oversight is essential for high-risk populations.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA